Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$137,500.00

Advancing Locally Activated Chemotherapy Using Computational Enzyme Design

FY 2015-16

Summary
Chemotherapy's major failing comes from the fact that it damages all cells in the body. This causes side-effects in patients, and limits the dose of the drug. The cancer can then become resistant to the drug, causing the patient to relapse. To counteract this, we need to develop methods to restrict the drug's effect to the tumour site. One approach to solving this problem involves the administration of an inactive form of the drug. An "activator protein" that activates the drug is then administered. This activator protein is linked to an antibody that will attach the protein to the tumour very specifically. By using an activator protein that isn't native to humans, the drug is activated only at the tumour site, thereby limiting side effects. This technique showed a lot of promise in the clinic. Unfortunately, the patients had an immune reaction to the foreign activator protein, causing this strategy to be abandoned in the early 2000s. To overcome this, we aim to use cutting-edge computational protein design technologies to re-program a human protein to activate the drug. The exterior of the activator protein that is "seen" by the immune system will look human, but its activity will be that of the foreign, drug activating protein. In this way, the activator protein can evade the immune system by tricking it into thinking that it is one of the patient's proteins. This will overcome the main limitation of this chemotherapy strategy, and allow us to use more frequent, higher doses of the drug without making the patient sick, reducing the frequency of drug resistance and relapse in patients. We are also designing these proteins to be inactive until they reach the tumour, thereby avoiding off-target activation of the drug by the enzyme that is still circulating freely in the bloodstream. This strategy can revolutionize cancer therapy. By limiting side effects and preventing relapses, we hope to make chemotherapy both more successful and less damaging in the future.
Program
CIHR Fellowship
Location
New Jersey, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
338443
Name
Yachnin Brahm J
Region
New Jersey
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Advancing Locally Activated Chemotherapy Using Computational Enzyme Design
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$137,500
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adept; Cancer; Chemotherapy; Computational Biology; Enzyme Design; Immunology; Prodrug; Rosetta
Abstract
Chemotherapy's major failing comes from the fact that it damages all cells in the body. This causes side-effects in patients, and limits the dose of the drug. The cancer can then become resistant to the drug, causing the patient to relapse. To counteract this, we need to develop methods to restrict the drug's effect to the tumour site. One approach to solving this problem involves the administration of an inactive form of the drug. An "activator protein" that activates the drug is then administered. This activator protein is linked to an antibody that will attach the protein to the tumour very specifically. By using an activator protein that isn't native to humans, the drug is activated only at the tumour site, thereby limiting side effects. This technique showed a lot of promise in the clinic. Unfortunately, the patients had an immune reaction to the foreign activator protein, causing this strategy to be abandoned in the early 2000s. To overcome this, we aim to use cutting-edge computational protein design technologies to re-program a human protein to activate the drug. The exterior of the activator protein that is "seen" by the immune system will look human, but its activity will be that of the foreign, drug activating protein. In this way, the activator protein can evade the immune system by tricking it into thinking that it is one of the patient's proteins. This will overcome the main limitation of this chemotherapy strategy, and allow us to use more frequent, higher doses of the drug without making the patient sick, reducing the frequency of drug resistance and relapse in patients. We are also designing these proteins to be inactive until they reach the tumour, thereby avoiding off-target activation of the drug by the enzyme that is still circulating freely in the bloodstream. This strategy can revolutionize cancer therapy. By limiting side effects and preventing relapses, we hope to make chemotherapy both more successful and less damaging in the future.
Competitiondate
201511
Approvedterm2
2 yrs 9 mths
Pinamesdelim
Yachnin, Brahm J
Approvedterm
2 ans 9 mois
Cihrcontribution2
~ $137,500~ $0~